Chronic Kidney Disease-Mineral Bone Metabolism (CKD-MBD) is a prevalent comorbid condition linked with unfavorable outcome. This syndrome encompasses laboratory, bone tissue derangements as well as cardiovascular and soft tissue calcification. Epidemiological studies suggest that as the glomerular filtration rate declines (GFR), several laboratory abnormalities become progressively more prevalent. Although it isn’t clear at the current time what is the primum movens, it has been repeatedly documented that serum levels of vitamin D, parathyroid hormone (PTH), calcium, phosphate and fibroblast growth factor 23 (FGF23) are commonly disrupted since the earlier stages of CKD. Of importance, in vitro evidence suggest that calcium, phosphate, vitamin D promote vascular calcification supporting the notion of a plausible link between serum biomarkers and soft tissue as well as vascular calcification occurrence. In turn, vascular calcification reduces large artery compliance and is associated with the occurrence of major cardiovascular events and the risk of death. Herein is reviewed current evidence on CKD-MBD physiopathology as well as treatments and therapeutic strategies for CKD-MBD.

Chronic kidney disease - mineral bone disease (CKD-MBD): Present and future perspectives / A. Bellasi, M. Cozzolino, A. Galassi - In: Comorbidities in chronic kidney disease: from diagnosis to treatment / [a cura di] L. di Lullo. - [s.l] : Nova Science Publishers, Inc., 2016 Apr. - ISBN 9781634850872. - pp. 47-66

Chronic kidney disease - mineral bone disease (CKD-MBD): Present and future perspectives

M. Cozzolino
Secondo
;
2016

Abstract

Chronic Kidney Disease-Mineral Bone Metabolism (CKD-MBD) is a prevalent comorbid condition linked with unfavorable outcome. This syndrome encompasses laboratory, bone tissue derangements as well as cardiovascular and soft tissue calcification. Epidemiological studies suggest that as the glomerular filtration rate declines (GFR), several laboratory abnormalities become progressively more prevalent. Although it isn’t clear at the current time what is the primum movens, it has been repeatedly documented that serum levels of vitamin D, parathyroid hormone (PTH), calcium, phosphate and fibroblast growth factor 23 (FGF23) are commonly disrupted since the earlier stages of CKD. Of importance, in vitro evidence suggest that calcium, phosphate, vitamin D promote vascular calcification supporting the notion of a plausible link between serum biomarkers and soft tissue as well as vascular calcification occurrence. In turn, vascular calcification reduces large artery compliance and is associated with the occurrence of major cardiovascular events and the risk of death. Herein is reviewed current evidence on CKD-MBD physiopathology as well as treatments and therapeutic strategies for CKD-MBD.
Medicine (all)
Settore MED/14 - Nefrologia
apr-2016
https://www.novapublishers.com/catalog/product_info.php?products_id=58236
Book Part (author)
File in questo prodotto:
File Dimensione Formato  
978-1-63485-087-2_eBook.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.29 MB
Formato Adobe PDF
4.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/612239
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact